Data as of Dec 11
| +0.02 / +0.17%|
The 8 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 25.00 and a low estimate of 13.50. The median estimate represents a +33.44% increase from the last price of 11.99.
The current consensus among 8 polled investment analysts is to Buy stock in Tetraphase Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.